Alkem Lab: Nomura Holdings maintains Buy on Alkem Laboratories with target price of ₹6,890; 4Q revenue was in line while EBITDA beat estimates by 11% driven by strong gross margin expansion to 65.4% (+606bps YoY), though PAT was impacted by one-off exceptional losses of ₹1.35bn related to real estate impairment and labour code changes along with a higher tax rate, while FY27 guidance was in line to ahead of expectations and the stock trades at 23.6x/19.7x FY27F/FY28F adjusted EPS.

 29 May 2026 09:08 AM

Alkem Lab: Nomura Holdings maintains Buy on Alkem Laboratories with target price of ₹6,890; 4Q revenue was in line while EBITDA beat estimates by 11% driven by strong gross margin expansion to 65.4% (+606bps YoY), though PAT was impacted by one-off exceptional losses of ₹1.35bn related to real estate impairment and labour code changes along with a higher tax rate, while FY27 guidance was in line to ahead of expectations and the stock trades at 23.6x/19.7x FY27F/FY28F adjusted EPS.

ALKEM LAB: Q4 CONS NET PROFIT RUPEES2.36B VS 3.1B (YOY) || Q4 REVENUE RUPEES 36B VS 31.4B (YOY)

 28 May 2026 01:49 PM

ALKEM LAB: Q4 CONS NET PROFIT RUPEES2.36B VS 3.1B (YOY) || Q4 REVENUE RUPEES 36B VS 31.4B (YOY)

ALKEM LAB: Q4 EBITDA RUPEES 5.17B VS 3.9B (YOY) || Q4 EBITDA MARGIN 14.4 % VS 12.45% (YOY)

 28 May 2026 01:50 PM

ALKEM LAB: Q4 EBITDA RUPEES 5.17B VS 3.9B (YOY) || Q4 EBITDA MARGIN 14.4 % VS 12.45% (YOY)

Alkem Laboratories: Gets 7 Observations From US FDA After Inspecting Daman Facility.

 02 May 2026 01:35 PM

Alkem Laboratories: Gets 7 Observations From US FDA After Inspecting Daman Facility.

Alkem Lab: Co CEO Was Domestic Pharma Business Veteran At Cipla And He Was Brought To Grow Chronic Franchise || Now With His Exit Improvement In Chronic Franchise Seems Gone

 24 Apr 2026 02:53 PM

Alkem Lab: Co CEO Was Domestic Pharma Business Veteran At Cipla And He Was Brought To Grow Chronic Franchise || Now With His Exit Improvement In Chronic Franchise Seems Gone

Alkem Laboratories: Co CEO Dr. Vikas Gupta Resigns To Pursue New Opportunities, Will Stay Until June 30, 2026 For Smooth Handover.

 24 Apr 2026 02:28 PM

Alkem Laboratories: Co CEO Dr. Vikas Gupta Resigns To Pursue New Opportunities, Will Stay Until June 30, 2026 For Smooth Handover.

Alkem Laboratories: Incorporates Its Wholly Owned Dubai Subsidiary, Alkem Pharma Trading FZCO, In The UAE

 13 Apr 2026 03:43 PM

Alkem Laboratories: Incorporates Its Wholly Owned Dubai Subsidiary, Alkem Pharma Trading FZCO, In The UAE

Alkem Laboratories: Launches “A To Z Daily,” A New Multivitamin For Energy, Immunity, And Stress Support.

 07 Apr 2026 03:27 PM

Alkem Laboratories: Launches “A To Z Daily,” A New Multivitamin For Energy, Immunity, And Stress Support.

Alkem Laboratories: Board Approves Bigger Investment For New Greenfield Formulations Plant In Ujjain, Rises To ₹1,036 Crores From ₹533 Crores, To Be Done In Phases.

 02 Apr 2026 01:02 PM

Alkem Laboratories: Board Approves Bigger Investment For New Greenfield Formulations Plant In Ujjain, Rises To ₹1,036 Crores From ₹533 Crores, To Be Done In Phases.

Alkem Labs: Company Incorporates A Fully Owned Subsidiary In Dubai Healthcare City, UAE

 30 Mar 2026 05:45 PM

Alkem Labs: Company Incorporates A Fully Owned Subsidiary In Dubai Healthcare City, UAE

Alkem Lab: Launches Semaglutide Injection In India With Weekly Treatment Cost Of INR 450

 21 Mar 2026 12:39 PM

Alkem Lab: Launches Semaglutide Injection In India With Weekly Treatment Cost Of INR 450

Alkem Laboratories: Gets GMP Compliance Certificate From Malta Medicines Authority For Daman Facility, Valid For 3 Years Starting December 9, 2025.

 20 Mar 2026 10:03 PM

Alkem Laboratories: Gets GMP Compliance Certificate From Malta Medicines Authority For Daman Facility, Valid For 3 Years Starting December 9, 2025.

Alkem Lab: Company Acquires 30 Acres Of Land From DMIC Vikram Udyogpuri Limited In Ujjain, Board Greenlights ₹533 Crore Investment For New Formulations Factory

 18 Mar 2026 07:57 PM

Alkem Lab: Company Acquires 30 Acres Of Land From DMIC Vikram Udyogpuri Limited In Ujjain, Board Greenlights ₹533 Crore Investment For New Formulations Factory

Alkem Lab: Co's Subsidiary Signs Deal To Buy 51%-55% Stake In Occlutech Holding AG, Progressing On Previously Announced Agreement

 06 Mar 2026 05:22 PM

Alkem Lab: Co's Subsidiary Signs Deal To Buy 51%-55% Stake In Occlutech Holding AG, Progressing On Previously Announced Agreement

Jefferies on Alkem Labs Buy, TP Rs 6550

 19 Feb 2026 08:23 AM

Jefferies on Alkem Labs Buy, TP Rs 6550

Alkem Lab: USFDA Finishes Pre-Approval Inspection At Enzene Biosciences; Issues 6 Procedural Observations But Confirms No Data Integrity Issues.

 16 Feb 2026 03:02 PM

Alkem Lab: USFDA Finishes Pre-Approval Inspection At Enzene Biosciences; Issues 6 Procedural Observations But Confirms No Data Integrity Issues.

Alkem Laboratories: Reports 5.5% Growth In Indian Business For Q3, Falling Short Of H2FY26 Target Of Double Digit Growth.

 13 Feb 2026 02:19 PM

Alkem Laboratories: Reports 5.5% Growth In Indian Business For Q3, Falling Short Of H2FY26 Target Of Double Digit Growth.

ALKEM LABORATORIES LTD: CO. TO ACQUIRE 51%-55% STAKE IN OCCLUTECH HOLDING AG FOR CASH CONSIDERATION; TARGET ENTITY ENGAGED IN MINIMALLY INVASIVE CARDIAC IMPLANTS; ACQUISITION EXPECTED TO BE COMPLETED BY JUNE 30, 2026.

 13 Feb 2026 02:04 PM

ALKEM LABORATORIES LTD: CO. TO ACQUIRE 51%-55% STAKE IN OCCLUTECH HOLDING AG FOR CASH CONSIDERATION; TARGET ENTITY ENGAGED IN MINIMALLY INVASIVE CARDIAC IMPLANTS; ACQUISITION EXPECTED TO BE COMPLETED BY JUNE 30, 2026.

Alkem Laboratories: To Buy 51%-55% Share In Occlutech Holding AG For €180.70 Million; Deal Expected To Close By June 30, 2026; Occlutech Specializes In Minimally Invasive Cardiac Implants With Revenue Of €49.38 Million In 2025.

 13 Feb 2026 02:11 PM

Alkem Laboratories: To Buy 51%-55% Share In Occlutech Holding AG For €180.70 Million; Deal Expected To Close By June 30, 2026; Occlutech Specializes In Minimally Invasive Cardiac Implants With Revenue Of €49.38 Million In 2025.

ALKEM LABORATORIES: Q3 CONS NET PROFIT 6.4B RUPEES VS 6.3B (YOY); EST 6.7B

 13 Feb 2026 01:51 PM

ALKEM LABORATORIES: Q3 CONS NET PROFIT 6.4B RUPEES VS 6.3B (YOY); EST 6.7B